The modification with ZPD‐L1 not only granted the nanoplatform strong tumor targeting ability but also effectively blocked the PD‐1/PD‐L1 interaction, further reversing immune T‐cell suppression and amplifying RT‐induced ICD. The gene discussed is CD274; the disease is neoplasm.